Samir N. Khleif

Samir N. Khleif publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Samir N. Khleif sits on this spectrum.

Samir N. Khleif D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Samir N. Khleif sits on this spectrum.

Best Publications

• Cancer classification using the Immunoscore: a worldwide task force

  Jérôme Galon;Franck Pagès;Francesco M Marincola;Francesco M Marincola;Helen K Angell;Helen K Angell

  961
  Citations

• PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.

  Vivek Verma;Vivek Verma;Rajeev K Shrimali;Rajeev K Shrimali;Shamim Ahmad;Winjie Dai

  319
  Citations

• Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

  Dmitriy Zamarin;Robert A. Burger;Michael W. Sill;Daniel J. Powell

  316
  Citations

• Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?

  Sandra Demaria;Chandan Guha;Jonathan Schoenfeld;Zachary Morris

  268
  Citations

• Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

  Sacha Gnjatic;Vincenzo Bronte;Laura Rosa Brunet;Marcus O. Butler

  249
  Citations

• Future perspectives in melanoma research

  Paolo A. Ascierto;Sanjiv Agarwala;Gerardo Botti;Alessandra Cesano

  246
  Citations

• Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation

  Unknown

  203
  Citations

• Defining the critical hurdles in cancer immunotherapy

  Bernard A. Fox;Bernard A. Fox;Dolores J. Schendel;Lisa H. Butterfield;Steinar Aamdal

  190
  Citations

• Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

  Asha Nayak-Kapoor;Zhonglin Hao;Ramses Sadek;Robin Dobbins

  173
  Citations

• A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.

  S N Khleif;S I Abrams;J M Hamilton;E Bergmann-Leitner

  169
  Citations

• MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects.

  Vivek Verma;Vivek Verma;Nazli Jafarzadeh;Shannon Boi;Subhadip Kundu

  169
  Citations

• Mutant KRAS conversion of conventional T cells into regulatory T cells

  Stephanie Zdanov;Magis Mandapathil;Rasha Abu Eid;Saudat Adamson-Fadeyi

  166
  Citations

• Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis

  Rajeev Kumar Shrimali;Shamim Ahmad;Vivek Verma;Peng Zeng

  166
  Citations

• Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.

  Rasha Abu-Eid;Raed N. Samara;Laurent Ozbun;Maher Y. Abdalla

  163
  Citations

• A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.

  Jose Lutzky;Scott Joseph Antonia;Andy Blake-Haskins;Xia Li

  146
  Citations

• Anti‐PD‐1 synergizes with cyclophosphamide to induce potent anti‐tumor vaccine effects through novel mechanisms

  Unknown

  144
  Citations

• Clinical trial designs for the early clinical development of therapeutic cancer vaccines

  Richard M. Simon;Seth M. Steinberg;Michael Hamilton;Allan Hildesheim

  144
  Citations

• Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers.

  Antoun Toubaji;Moujahed Achtar;Maurizio Provenzano;Vincent E. Herrin

  141
  Citations

• Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)

  Alessandro D. Santin;Wei Deng;Michael Frumovitz;Natalia Buza

  138
  Citations

• A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

  Osama E. Rahma;Ed Ashtar;Malgorzata Czystowska;Marta E. Szajnik

  132
  Citations